Clinicians managing people with idiopathic pulmonary fibrosis (IPF) are left with few options once the disease seriously progresses, despite pirfenidone treatment. Now a study shows that continuing treatment is the best way to move forward, as it is likely to prevent an even greater decline in lung function and improve life expectancy.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?